The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index; 2 of the 53 sources its claims cite were checked for support.
Recommendations for the management of tyrosinaemia type 1
Open accessAbstract
The management of tyrosinaemia type 1 (HT1, fumarylacetoacetase deficiency) has been revolutionised by the introduction of nitisinone but dietary treatment remains essential and the management is not easy. In this review detailed recommendations for the management are made based on expert opinion, published case reports and investigational studies as the evidence base is limited and there are no prospective controlled studies. The added value of this paper is that it summarises in detail current clinical knowledge about HT1 and makes recommendations for the management.
Overview
CoChat Summary
## TL;DR
This paper provides expert-opinion recommendations for managing tyrosinaemia type 1, emphasizing rapid nitisinone initiation plus lifelong dietary treatment and close monitoring. It is not based on prospective controlled studies, and the authors explicitly frame the advice as recommendations rather than formal guidelines.
## Key findings
- Nitisinone has “revolutionised” management, and the recommended immediate dose is 1 mg/kg/day once daily; for acute severe liver failure, 2 mg/kg/day for 48 hours is recommended.
- Response is usually rapid: coagulation improves within 48 hours, all patients should respond within a week, and succinylacetone in blood and urine should no longer be detectable after the first 24 hours.
- Long-term risk remains important even on treatment, especially hepatocellular carcinoma (HCC); the paper recommends hepatic imaging at least every 6 months, with MRI/CT every year if the liver is uniform, or every 3–6 months if nodules are present.
- Dietary management targets plasma tyrosine at 200–400 μmol/l up to about age 12, with some centres allowing up to 500 μmol/l; the paper notes that the safety of allowing higher levels later is not known.
## Methods
- The paper is an expert consensus review developed by an ad hoc working group of clinicians from Europe and Canada with extensive HT1 experience.
- The authors state that the literature was reviewed, but evidence was insufficient for formal guidelines; the recommendations were drafted, revised in a workshop, circulated, and iterated until agreement.
- The recommendations are grounded in published case reports, investigational studies, expert opinion, and unpublished data, with the authors explicitly noting that there were no prospective controlled studies.
## Limitations
- Stated in the paper: the evidence base is limited, there are no prospective controlled studies, and the output is therefore recommendations rather than formal guidelines.
- Stated in the paper: several management targets are uncertain, including the optimal plasma nitisinone concentration, the target plasma tyrosine/phenylalanine levels, and the safety of higher tyrosine levels after age 12.
- Evident from the text: this is an expert consensus/review, so its recommendations depend heavily on specialist opinion and indirect evidence rather than comparative trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
2 Valid · 25 Not valid · 36 Not checked · 21 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients may present in infancy, childhood or as adults [1,8].”
§ Recommendations for the management of tyrosinaemia type 1 > Clinical presentation and diagnosis > Timing of presentation
What the sources say
- Not checked — no full text of the sourcecites [1] Chakrapani A, Gissen P, McKiernan P: Disorders of Tyrosine Metabolism. Inborn Metabolic Diseases. 5th edition. Edited by: Saudubray J-M, Berghe G, Walter JH. Heidelberg: Springer; 2012:275-276. Chapter 18. source
- Partly supportedcites [8] van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V, Berger R, Heymans HS: Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology. 1994, 20: 1187-1191. 10.1002/hep.1840200513. sourceExperimental — accuracy not yet measured
The Abstract (p.1) of our copy supports presentation in infancy and childhood: the acute form 'manifests severe liver disease before 6 mo of age', the subacute form begins 'in the second half of the first year', and the chronic form manifests 'after 1 yr of age'; the Results and Discussion likewise stratify onset as <2 mo, 2-6 mo and >6 mo, with HCC occurring at 'almost 2 to 12 yr of age'. However, nothing in our copy states that patients may present as adults — the only mention of adults is in the title of a cited reference (Kvittingen et al., renal failure in adult patients, ref. 20), not a finding the paper reports or relies on. The 'or as adults' part of the triad is therefore not supported by this source. (LLM, conf=0.72)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“start nitisinone (NTBC, Orfadin®,) in a dose of 1 mg/kg/d once a day as the half life is 54 hrs [19,20].”
§ Recommendations for the management of tyrosinaemia type 1 > Immediate management
What the sources say
- Supportedcites [19] Hall MG, Wilks MF, Provan WM, Eksborg S, Lumholtz B: Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. Br J Clin Pharmacol. 2001, 52: 169-177. 10.1046/j.0306-5251.2001.01421.x. source
The Discussion states that NTBC (nitisinone) has a plasma half-life of approximately 54 hours. The study measured this after a single dose in healthy male volunteers; it does not establish the once-daily dosing recommendation, which is outside the claim being judged. (LLM, conf=0.95)
- Not checked — no full text of the sourcecites [20] Schlune A, Thimm E, Herebian D, Spiekerkoetter U: Single dose NTBC treatment of hereditary tyrosinaemia type 1. J Inherited Metab Dis. 2012, 35: 831-836. 10.1007/s10545-012-9450-9. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
In the paper
“These patients are particularly susceptible to infections [9].”
§ Recommendations for the management of tyrosinaemia type 1 > Clinical presentation and diagnosis > Timing of presentation
What the sources say
- Not checked — no full text of the sourcecites [9] Epov L, Srugo I, Kassis I, Bar-Joseph G, Mandel H, Kugelman A: 'Sick', irritable infant with fever, vomiting, bloody stool and abdominal distention (Case Presentation). Diagnosis: Hereditary tyrosinaemia type I presenting as E.coli septicaemia. Acta Paediatr. 2010, 99: 1437-1438. 10.1111/j.1651-2227.2010.01901.x. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Although biochemical abnormalities may be identified shortly after birth [14], babies with HT1 are rarely symptomatic in the first days of life.”
§ Recommendations for the management of tyrosinaemia type 1 > Clinical presentation and diagnosis > Timing of presentation
What the sources say
- Not checked — no full text of the sourcecites [14] Schlump JU, Mayatepek E, Spiekerkoetter U: Significant increase of succinylacetone within the first 12 h of life in hereditary tyrosinemia type 1. Eur J Pediatr. 2010, 169: 569-572. 10.1007/s00431-009-1074-1. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The presentation can be variable, even within one family.”
§ Recommendations for the management of tyrosinaemia type 1 > Clinical presentation and diagnosis > Timing of presentation
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
27 more claims
Create a free account to see all 84 claims and to verify the 2 references still open.
- It may state two separate claims as one. 35
- Probably not a substantial claim. 33
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Occasionally, nodules are present before initiation of NTBC-treatment but regress on repeated imaging following treatment [18].”
From Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice (2014) · cites this paper as [18]
Citations
Cites
Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
LINDSTEDT, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)92685-9 · Cited by 631 · cited 1×
“; licensee BioMed Centra Commons Attribution License (http://creativec reproduction in any medium, provided the or Nitisinone is a compound that has revolutionised the management of tyrosinaemia type 1 [3,4].”
BackgroundParikh, T., Drew, S. J., Lee, V. S., Wong, S., Hecht, E. M., Babb, J. S., & Taouli, B. (2008) · Radiology · doi:10.1148/radiol.2463070432 · Cited by 560 · cited 1×
“Diffusion-weighted imaging may help to distinguish well-differentiated hepatocellular carcinomas from benign nodules [17,18], C Dionisi Vici and L Monti unpublished.”
BackgroundInborn Metabolic Diseases: Diagnosis and Treatment
(2012) · doi:10.1007/978-3-642-15720-2 · Cited by 377
Inborn Metabolic Diseases: Diagnosis and Treatment
(2006) · Springer eBooks · doi:10.1007/978-3-540-28785-8 · Cited by 361
Tyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione)
Holme, E., & Lindstedt, S. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005410820201 · Cited by 264
NTBC treatment in tyrosinaemia type I: Long‐term outcome in French patients
Masurel‐Paulet, A., Poggi‐Bach, J., Rolland, M. ‐., Bernard, O., Guffon, N., Dobbelaere, D., Sarles, J., de Baulny, H. O., & Touati, G. (2008) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-008-0793-1 · Cited by 212 · cited 1×
“Many patients on nitisinone have learning difficulties [35] and it is widely thought that this is associated with the increased tyrosine concentrations.”
BackgroundVan Spronsen, F. J., Thomasse, Y., Smit, P. G. A., Leonard, J. V., Clayton, P. T., Fidler, V., Berger, R., & Heymans, H. S. A. (1994) · Hepatology · doi:10.1002/hep.1840200513 · Cited by 193
Self-citationGenetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean.
(1990) · Europe PMC (PubMed Central) · Cited by 163
Coenegrachts, K., Delanote, J., Ter Beek, L., Haspeslagh, M., Bipat, S., Stoker, J., Van Kerkhove, F., Steyaert, L., Rigauts, H., & W Casselman, J. (2007) · The British Journal of Radiology · doi:10.1259/bjr/33156643 · Cited by 149
Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec
Larochelle, J., Alvarez, F., Bussières, J.-F., Chevalier, I., Dallaire, L., Dubois, J., Faucher, F., Fenyves, D., Goodyer, P., Grenier, A., et al. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.05.022 · Cited by 137
Self-citation
Research works printed but not linked: 1
- Larochelle J, Alvarez F, Bussières JF, Chevalier I, Dallaire L, Dubois J, Faucher F, Fenyves D, Goodyer P, Grenier A, Holme E, Laframboise R, Lambert M, Lindstedt S, Maranda B, Melançon S, Merouani A, Mitchell J, Parizeault G, Pelletier L, Phan V, Rinaldo P, Scott CR, Scriver C, Mitchell GA: Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec. Mol Genet Metab. 2012, Epub ahead of print
Cited by
Squires, R. H., Ng, V., Romero, R., Ekong, U., Hardikar, W., Emre, S., & Mazariegos, G. V. (2014) · Hepatology · doi:10.1002/hep.27191 · Cited by 254
“42 years between 1999-2008.(285) Failure to respond to NTBC within a week may be due to noncompliance or subtherapeutic NTBC, manifested by persistence of succinylacetone in the urine, or a fulminant course despite therapy.”
BackgroundChinsky, J. M., Singh, R., Ficicioglu, C., van Karnebeek, C. D. M., Grompe, M., Mitchell, G., Waisbren, S. E., Gucsavas-Calikoglu, M., Wasserstein, M. P., Coakley, K., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.101 · Cited by 247
Self-citationConjunctivitis: A Systematic Review
A. Azari, A., & Arabi, A. (2020) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v15i3.7456 · Cited by 179
“, Reiter’s, Stevens-Johnson syndrome (SJS), and keratoconjunctivitis sicca in rheumatoid arthritis], nutritional deprivation (vitamin A deficiency), and congenital metabolic syndromes (RichnerHanhart syndrome and porphyria)[4, 5] (Table 1).”
BackgroundMayorandan, S., Meyer, U., Gokcay, G., Segarra, N. G., de Baulny, H. O., van Spronsen, F., Zeman, J., de Laet, C., Spiekerkoetter, U., Thimm, E., et al. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-014-0107-7 · Cited by 131
“Occasionally, nodules are present before initiation of NTBC-treatment but regress on repeated imaging following treatment [18].”
Self-citationSquires, J. E., McKiernan, P. J., & Squires, R. H. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.06.009 · Cited by 139
Self-citation
Metadata
- Authors
- de Laet, C., Dionisi-Vici, C., Leonard, J. V., McKiernan, P., Mitchell, G., Monti, L., de Baulny, H. O., Pintos-Morell, G., & Spiekerkötter, U.
- Affiliations
- University College London (GB)
- Birmingham Children's Hospital (GB)
- Centre Hospitalier Universitaire Sainte-Justine (CA)
- Bambino Gesù Children's Hospital (IT)
- Corresponding author
- Leonard, James V
- Venue
- Orphanet Journal of Rare Diseases
- Published
- 2013-01-11
- Volume
- 8
- Issue
- 1
- Pages
- 8-8
- ISSN
- 1750-1172 (ISSN-L)
- PMC
- PMC3558375
- OpenAlex
- W2097721154
- Semantic Scholar
- 5d5e15a07fbab403a889841bf40c6bc0f93682bd
- Cited by
- 227
- References
- 49
- Citations by year
- 2026: 3 · 2025: 14 · 2024: 18 · 2023: 12 · 2022: 14 · 2021: 25 · 2020: 17 · 2019: 22 · 2018: 17 · 2017: 33 · 2016: 15 · 2015: 18 · 2014: 15 · 2013: 3
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Orphanet Journal of Rare Diseases (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Swedish Orphan Biovitrum
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- nitisinone, dietary therapy, inborn errors of metabolism, management recommendations, hyperphenylalaninemia
- MeSH terms
- Cyclohexanones, Female, Humans, Infant, Newborn, Nitrobenzoates, Pregnancy, Psychometrics, Bone Density, Neonatal Screening, Liver Transplantation, Tyrosinemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recommendations for the management of tyrosinaemia type 1. https://app.cochat.ai/papers/10.1186/1750-1172-8-8
- The paper
- de Laet, C., Dionisi-Vici, C., Leonard, J. V., McKiernan, P., Mitchell, G., Monti, L., de Baulny, H. O., Pintos-Morell, G., & Spiekerkötter, U. (2013). Recommendations for the management of tyrosinaemia type 1. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/1750-1172-8-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.